

1 **Hemodynamic Differences Between Women and Men with Elevated Blood Pressure in**  
2 **China: A Non-Invasive Assessment of 45,082 Adults Using Impedance Cardiography**  
3 **Short title: Hemodynamic Sex Differences in Elevated Blood Pressure**

4  
5 César Caraballo,<sup>1,2</sup> Shiwani Mahajan,<sup>1,2</sup> Jianlei Gu,<sup>3,4</sup> Yuan Lu,<sup>1</sup> Erica S. Spatz,<sup>1,2</sup> Rachel P.  
6 Dreyer,<sup>5</sup> MaoZhen Zhang,<sup>6,7</sup> NingLing Sun,<sup>8</sup> Yihong Ren,<sup>9</sup> Xin Zheng,<sup>10</sup> Hongyu Zhao,<sup>3,11</sup> Hui  
7 Lu,<sup>3,12</sup> Zheng J. Ma,<sup>3,11,13</sup> Harlan M. Krumholz<sup>1,2,14,\*</sup>

8  
9 <sup>1</sup> Center for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven,  
10 Connecticut, United States of America

11 <sup>2</sup> Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of  
12 Medicine, Yale University, New Haven, Connecticut, United States of America

13 <sup>3</sup> SJTU-Yale Joint Center for Biostatistics, School of Life Science and Biotechnology, Shanghai  
14 Jiao Tong University, Shanghai, China

15 <sup>4</sup> Shanghai Engineering Research Center for Big Data in Pediatric Precision Medicine, Shanghai,  
16 China

17 <sup>5</sup> Department of Emergency Medicine, Yale School of Medicine, New Haven, CT, United States

18 <sup>6</sup> iKang Healthcare Group, Inc., Shanghai, China

19 <sup>7</sup> Department of Cardiology, Xinhua Hospital Affiliated with Shanghai Jiao Tong University

20 <sup>8</sup> Department of Hypertension at Heart Center, Peking University People's Hospital, Beijing,  
21 China

22 <sup>9</sup> The First Medical Center of Chinese PLA General Hospital, Beijing, China

23 <sup>10</sup> National Clinical Research Center of Cardiovascular Diseases, State Key Laboratory of  
24 Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese  
25 Academy of Medical Sciences and Peking Union Medical College, Beijing, China

26 <sup>11</sup> Department of Biostatistics, School of Public Health, Yale University, New Haven,  
27 Connecticut, United States of America

28 <sup>12</sup> Center for Biomedical Informatics, Shanghai Children's Hospital, Shanghai, China  
29 School of Medicine, Shanghai, China

30 <sup>13</sup> Beijing Li-Heng Medical Technologies, Ltd, Beijing, China

31 <sup>14</sup> Department of Health Policy and Management, Yale School of Public Health, New Haven,  
32 Connecticut, United States of America

33

34 **\*Corresponding author**

35 Email: [harlan.krumholz@yale.edu](mailto:harlan.krumholz@yale.edu)

## 1 **Abstract**

2 **Background:** Whether there are sex differences in hemodynamic profiles among people with  
3 elevated blood pressure is not well understood and could guide personalization of treatment.

4 **Methods and results:** We described the clinical and hemodynamic characteristics of adults with  
5 elevated blood pressure in China using impedance cardiography. We included 45,082 individuals  
6 with elevated blood pressure (defined as systolic blood pressure of  $\geq 130$  mmHg or a diastolic  
7 blood pressure of  $\geq 80$  mmHg), of which 35.2% were women. Overall, women had a higher mean  
8 systolic blood pressure than men (139.0 [ $\pm 15.7$ ] mmHg vs 136.8 [ $\pm 13.8$ ] mmHg,  $P < 0.001$ ), but a  
9 lower mean diastolic blood pressure (82.6 [ $\pm 9.0$ ] mmHg vs 85.6 [ $\pm 8.9$ ] mmHg,  $P < 0.001$ ). After  
10 adjusting for age, region, and body mass index, women  $< 50$  years old had lower systemic  
11 vascular resistance index (beta-coefficient [ $\beta$ ] -31.7; 95% CI: -51.2, -12.2) and higher cardiac  
12 index ( $\beta$  0.07; 95% CI: 0.04, 0.09) than men of their same age group, whereas among those  $\geq 50$   
13 years old women had higher systemic vascular resistance index ( $\beta$  120.4; 95% CI: 102.4, 138.5)  
14 but lower cardiac index ( $\beta$  -0.15; 95% CI: -0.16, -0.13). Results were consistent with a  
15 propensity score matching sensitivity analysis, although the magnitude of the SVRI difference  
16 was lower and non-significant. However, there was substantial overlap between women and men  
17 in the distribution plots of these variables, with overlapping areas ranging from 78% to 88%.

18 **Conclusions:** Our findings indicate that there are sex differences in hypertension phenotype, but  
19 that sex alone is insufficient to infer an individual's profile.

20

## 21 **Introduction**

22           Mean arterial pressure is determined by cardiac output (CO) and systemic vascular  
23 resistance (SVR), and there are important sex-specific differences in its regulation and the risk of  
24 developing hypertension.[1-4] Recent studies[5-7] have shown that, on average, women with  
25 hypertension have a higher SVR and a lower CO when compared with men. Such observations  
26 suggest that sex could serve as a proxy for the underlying hemodynamic phenotype among  
27 individuals with elevated blood pressure. Considering that tailoring antihypertensive treatment  
28 based on individuals' hemodynamic profile may be associated with better blood pressure  
29 control,[8-11] these sex differences on hemodynamic phenotypes could help to identify more  
30 personalized therapeutic approaches. However, current hypertension guidelines have no sex-  
31 specific recommendations on therapy—other than in pregnancy—due to a lack of evidence of  
32 benefit from sex-stratified therapies.[12, 13]

33           Most of the studies addressing these underlying hemodynamic sex differences have had  
34 small samples or focused exclusively on younger individuals,[5, 6] which limits the  
35 generalizability of their findings to a broader population that includes the elderly, among whom  
36 the hypertension burden is greater.[14-16] Particularly, after menopause, women experience a  
37 sharp increase in hypertension prevalence,[17-19] eventually surpassing aged-matched men.[20]  
38 Thus, assessing the sex-specific differences in hemodynamic profiles across age groups can  
39 provide a better understanding on whether there are substantial hemodynamic differences by sex  
40 that could be used to guide therapy.

41           Accordingly, we used data from tens of thousands of individuals with elevated blood  
42 pressure from an outpatient setting in China to evaluate the overall patterns of sex differences in  
43 hemodynamic variables and to determine how these sex hemodynamic differences may vary with

44 age. We also aimed to evaluate the distribution of these variables among women and men, and to  
45 what extent they overlap by sex. Furthermore, we stratified our analysis at the mean age of  
46 menopause in China because of its association with hemodynamic changes. Results from this  
47 study can advance our understanding of the association of sex with hemodynamic patterns in  
48 people with hypertension and suggest if sex could be used to guide therapy.

49

## 50 **Methods**

### 51 **Data source**

52 iKang Health Group provided the de-identified data used in this study to SJTU-Yale Joint  
53 Center for Biostatistics in Shanghai, China. This is where all data are stored and all analyses  
54 were performed. Requests for data can be submitted to the iKang Health Group at  
55 [maozhen.zhang@ikang.com](mailto:maozhen.zhang@ikang.com). The code used to analyze the data is publicly available at  
56 <https://www.doi.org/10.5281/zenodo.5931975>.

57

### 58 **Study population**

59 Between January 2012 and October 2018, 116,851 individuals (65,172 men and 51,679  
60 women) underwent an impedance cardiography (ICG) test offered as part of the employee  
61 routine annual physical examination at 51 sites of iKang Health Checkup Centers throughout  
62 China. We excluded those younger than 20 years and those older than 80 years (n=839). Then,  
63 we excluded 1,814 individuals with outlier values of weight, height, blood pressure, heart rate,  
64 stroke volume, and baseline thoracic impedance (**Fig 1**). Of the 114,198 remaining individuals,  
65 we included 45,082 with elevated blood pressure, which was defined as a systolic blood pressure

66 (SBP) of  $\geq 130$  mmHg or a diastolic blood pressure (DBP) of  $\geq 80$  mmHg, consistent with the  
67 2017 American College of Cardiology/American Heart Association hypertension guidelines.[12]

68

69 **Fig 1. Study population flowchart.** Abbreviations: ICG, impedance cardiography; DBP,  
70 diastolic blood pressure; SBP, systolic blood pressure; SV, stroke volume; HR, heart rate;  
71 Z0, baseline impedance.

72

### 73 **Data collection**

74 At health centers, nurses collected information on the patient's age, sex, geographical  
75 region, weight, height, SBP, and DBP. Weight was measured using a calibrated and standardized  
76 scale, rounded to the nearest 0.1 kg. Height was measured to the nearest 0.1 cm using a portable  
77 stadiometer (Omron HNJ-318; Omron Corporation, Kyoto, Japan) with patients standing without  
78 shoes and heels against the wall. Body mass index (BMI) was calculated as weight in kilograms  
79 divided by the square of height in meters. After 5 minutes of resting in a seated position, blood  
80 pressure was measured once using an automated monitor (Omron HBP-9020; Omron  
81 Corporation, Kyoto, Japan) on the right arm.

82 Patients were then requested to lay supine and, after 3 minutes in this position, all  
83 hemodynamic parameters were measured using ICG. The ICG method that has been validated  
84 against invasive techniques for estimation of stroke volume and CO in both stable and high-risk  
85 populations,[21-23] and has been shown to be a highly reproducible technique.[24] By applying  
86 a constant, low amplitude, high-frequency, alternating electrical current to the thorax, ICG  
87 device measures the corresponding voltage to detect beat-to-beat changes in thoracic electrical  
88 resistance, known as impedance, and with it stroke volume is estimated.[25, 26] Then, using

89 heart rate, mean arterial blood pressure, and BMI, other hemodynamic parameters are calculated,  
90 including CO, cardiac index (CI), SVR, and systemic vascular resistance index (SVRI).[27] The  
91 ICG device used (CHM T3002/P3005, designed by Beijing Li-Heng Medical Technologies, Ltd,  
92 manufactured by Shandong Baoli hao Medical Appliances, Ltd.) was developed based on  
93 improved hardware and advanced digital filtering algorithms,[28] and has been validated versus  
94 both invasive thermodilution and non-invasive echocardiography in different settings.[29-31]  
95

## 96 **Variable definitions**

97 We described demographic characteristics and hemodynamic parameters of blood  
98 pressure in women and men overall and by age. Considering that the mean age of natural  
99 menopause in China is reported as approximately 50 years of age,[32-34] we stratified our study  
100 population as <50 years old and  $\geq 50$  years old. We used the World Health Organization  
101 recommended cutoff values for BMI classification in Asian populations, defining underweight as  
102  $<18.5 \text{ kg/m}^2$ , normal weight from  $18.5 \text{ kg/m}^2$  to  $<23 \text{ kg/m}^2$ , overweight from  $23 \text{ kg/m}^2$  to  $<27.5$   
103  $\text{kg/m}^2$ , and obesity as  $\geq 27.5 \text{ kg/m}^2$ . [35] We defined a predominantly vascular hypertension  
104 phenotype as high SVRI ( $>2400 \text{ dynes}\cdot\text{sec}\cdot\text{cm}^{-5}\cdot\text{m}^2$ ) with a low or normal CI ( $<2.5 \text{ L/min/m}^2$  or  
105  $2.5\text{--}4 \text{ L/min/m}^2$ , respectively), and predominantly cardiac hypertension phenotype as high CI ( $>4$   
106  $\text{L/min/m}^2$ ) with low or normal SVRI ( $<2000 \text{ dynes}\cdot\text{sec}\cdot\text{cm}^{-5}\cdot\text{m}^2$  or  $2000\text{--}2400 \text{ dynes}\cdot\text{sec}\cdot\text{cm}^{-5}\cdot\text{m}^2$ ,  
107 respectively).[11, 36, 37]

108

## 109 **Statistical analysis**

110 We calculated means with standard deviations (SD) for continuous variables and  
111 frequencies for categorical variables, and assessed for the significance of the inter-group

112 differences using ANOVA and Chi-square test (with Yates' correction), respectively. Next, the  
113 relationship between these parameters and age, BMI and SBP was evaluated using least squares  
114 method (LMS) curves.[38] To assess the association of sex with CO, CI, SVR, and SVRI we  
115 used unadjusted and sequential adjusted linear regression models and reported the female sex  
116 beta coefficient and its respective 95% confidence interval (95% CI) for the entire study  
117 population, among those <50 years old, and among those  $\geq$ 50 years old. The sequential adjusted  
118 models were built as follows: adjusted model 1 included age and region; model 2 included  
119 variables from model 1 plus BMI. Finally, we used density plots to characterize the distribution  
120 of the hemodynamic parameters by sex across the different strata, estimating the percentage of  
121 the plot area that overlaps between women and men on each stratum. To account for potential  
122 residual confounding, we performed a nearest neighbor propensity score matching sensitivity  
123 analysis, using region, age, SBP, DBP, and BMI. Propensity score generation and 1:1 match for  
124 samples between men and women groups were performed using the MatchIt package in R.[39]  
125 For reproducibility and comparison with prior studies, and aligned with Chinese hypertension  
126 guidelines cutoff blood pressure values,[40] we also performed a sensitivity analysis replicating  
127 these analyses on a subpopulation of individuals with SBP  $\geq$ 140 mmHg or DBP  $\geq$ 90 mmHg.

128 All statistical analyses were conducted using R, version 3.6.2 (The R Foundation for  
129 Statistical Computing). Statistical significance was defined as a 2-tailed  $P < 0.05$ . Coauthors JG,  
130 HZ, and ZJM take responsibility for the analysis.

131

## 132 **Ethics statement**



133 This project received an exemption from review from the Institutional Review Board at  
 134 Yale School of Medicine and at Shanghai Jiao Tong University College of Biotechnology as we  
 135 used de-identified data provided by the iKang Health group. Given that the de-identified data  
 136 were provided by a third party, we did not need to collect consent for participation.

137

## 138 **Results**

### 139 **Age, body mass index, and hemodynamic variables and phenotypes** 140 **by sex**

141 We included 45,082 individuals with elevated blood pressure, of which 15,888 (35.2%)  
 142 were women. Overall, women had a higher mean age than men (54.5 [ $\pm$ 11.8] years vs 48.0  
 143 [ $\pm$ 13.0] years,  $P < 0.001$ ) and were less likely to be obese (17.2% vs 23.5%,  $P < 0.001$ ) (Table 1).  
 144 Women had a higher mean SBP than men (139.0 [ $\pm$ 15.7] mmHg vs 136.8 [ $\pm$ 13.8] mmHg,  
 145 respectively,  $P < 0.001$ ), but a lower mean DBP (82.6 [ $\pm$ 9.0] mmHg vs 85.6 [ $\pm$ 8.9] mmHg,  $P <$   
 146 0.001). Among those  $< 50$  years of age, women had lower mean SBP and DBP compared with  
 147 men of the same age group ( $P < 0.001$  for each), whereas among those older than 50 years they  
 148 had higher mean SBP and lower mean DBP than men ( $P < 0.001$  for each) (**Table 1**).

149

150 **Table 1. Sex differences in clinical and hemodynamic variables by age group among adults**  
 151 **with elevated blood pressure.**

	All			$< 50$ years old			$\geq 50$ years old		
	Women N=15,888	Men N= 29194	P value	Women N = 4,384	Men N = 15,512	P value	Women N = 11,504	Men N = 13,682	P value
Age (years)	54.5 (11.8)	48.0 (13.0)	$< 0.001$	39.3 (8.1)	38.0 (7.3)	$< 0.001$	60.2 (6.9)	59.5 (7.2)	$< 0.001$
BMI (kg/m <sup>2</sup> )	24.4 (3.5)	25.5 (3.2)	$< 0.001$	23.5 (3.7)	25.7 (3.4)	$< 0.001$	24.8 (3.3)	25.2 (3.0)	$< 0.001$

	All			<50 years old			≥50 years old		
Obesity*	2733 (17.2%)	6858 (23.49%)	<0.001	585 (13.34%)	4057 (26.15%)	<0.001	2148 (18.67%)	2801 (20.47%)	<0.001
Region			<0.001			<0.001			<0.001
East	5965 (37.54%)	13275 (45.47%)		1956 (20.86%)	7419 (79.14%)		4009 (40.64%)	5856 (59.36%)	
North	3665 (23.07%)	4156 (14.24%)		779 (29.59%)	1854 (70.41%)		2886 (55.63%)	2302 (44.37%)	
South	2737 (17.23%)	4317 (14.79%)		686 (22.66%)	2341 (77.34%)		2051 (50.93%)	1976 (49.07%)	
Southwest	3521 (22.16%)	7446 (25.51%)		963 (19.81%)	3898 (80.19%)		2558 (41.89%)	3548 (58.11%)	
Blood pressure (mmHg)									
Systolic	139.0 (15.7)	136.7 (13.8)	<0.001	131.2 (13.2)	133.7 (12.2)	<0.001	142.0 (15.6)	140.1 (14.8)	<0.001
Diastolic	82.6 (9.00)	85.6 (8.9)	<0.001	83.3 (7.9)	85.3 (8.9)	<0.001	82.4 (9.4)	86.01 (9.0)	<0.001
Hypertension phenotype									
Predominantly cardiac <sup>†</sup>	2559 (16.11%)	5185 (17.76%)	<0.001	1382 (31.52%)	3495 (22.53%)	<0.001	1177 (10.23%)	1690 (12.35%)	<0.001
Predominantly vascular <sup>‡</sup>	9780 (61.56%)	16396 (56.16%)	<0.001	1666 (38.00%)	7197 (46.40%)	<0.001	8114 (70.53%)	9199 (67.23%)	<0.001
Low/normal CI & low/normal SVRI	3531 (22.22%)	7548 (25.86%)	<0.001	1,330 (30.34%)	4,790(30.88%)	0.50	2,201 (19.13%)	2,758 (20.16%)	0.04
High CI & high SVRI	18 (0.11%)	65 (0.22%)	0.01	6 (0.14%)	30 (0.19%)	0.56	12 (0.10%)	35 (0.26%)	0.01
ICG parameters									
Heart rate (bpm)	69.4 (11.4)	69.5 (11.3)	0.63	72.6 (11.9)	70.8 (11.1)	<0.001	68.2 (10.9)	68.0 (11.3)	0.15
Stroke volume (mL)	72.9 (18.6)	88.8 (21.5)	<0.001	80.0 (18.8)	93.0 (21.6)	<0.001	70.2 (17.7)	84.0 (20.5)	<0.001
CO (L/min)	5.0 (1.4)	6.1 (1.5)	<0.001	5.8 (1.4)	6.5 (1.4)	<0.001	4.7 (1.2)	5.6 (1.4)	<0.001
CI (L/min/m <sup>2</sup> )	3.2 (0.8)	3.3 (0.8)	<0.001	3.6 (0.9)	3.5 (0.7)	<0.001	3.0 (0.8)	3.2 (0.7)	<0.001
SVR (dynes·sec·cm <sup>-5</sup> )	1744 (523)	1433 (389)	<0.001	1471 (411)	1315 (324)	<0.001	1848 (524)	1565 (412)	<0.001
SVRI (dynes·sec·cm <sup>-5</sup> ·m <sup>2</sup> )	2734.1 (809.9)	2596.3 (677.2)	<0.001	2326.0 (658.0)	2435.1 (598.6)	<0.001	2889.6 (808.3)	2779.2 (713.8)	<0.001

Data are presented as mean (SD) for continuous variables and n (%) for categorical variables.

\* Obesity was defined as BMI ≥27.5 kg/m<sup>2</sup>

† A predominantly cardiac hypertension phenotype was determined by high CI with low or normal SVRI

‡ Predominantly vascular hypertension phenotype was determined by low or normal CI with high SVRI

Abbreviations: SD= Standard Deviation, BMI= Body Mass Index, ICG= Impedance Cardiography, SVR= Systemic Vascular Resistance, SVRI= Systemic Vascular Resistance Index, CO= Cardiac Output, CI= Cardiac Index.

152

153 Overall, women had lower mean CO and CI and higher mean SVR and SVRI than men

154 (P<0.001 for all). When stratified by age, women <50 years old had a higher mean CI and a

155 lower mean SVRI than men (P< 0.001 for both), whereas, among those older than 50 years,

156 women had a lower mean CI (P< 0.001) and a higher mean SVRI (P<0.001) (**Table 1**). Also,

157 compared with men, women were more likely to have predominantly vascular hemodynamic  
158 hypertension phenotype (61.6% vs 56.2%,  $P<0.001$ ) but only slightly less likely to have a  
159 predominantly cardiac phenotype (16.11% vs 17.8%,  $P<0.001$ ). Compared with men of the same  
160 age, women <50 years old were less likely to have a predominantly vascular phenotype and more  
161 likely to have a predominantly cardiac phenotype (38% vs 46.4% and 31.5% vs 22.5%,  
162 respectively,  $P<0.001$  for each comparison). Women older than 50 years, on the other hand,  
163 compared with men of the same age group, were more likely to have a predominantly vascular  
164 phenotype (70.5% vs 67.2%,  $P<0.001$ ) and less likely to have a predominantly cardiac phenotype  
165 (10.2% vs 12.4%,  $P<0.001$ ) (**Table 1**). Similar results were found in the sensitivity analysis  
166 among those with  $SBP \geq 140$  mmHg or  $DBP \geq 90$  mmHg, although in this subpopulation there  
167 was no significant difference in the mean CI and SVRI between men and women <50 years (**S1**  
168 **Table**).

169

## 170 **Relationship of hemodynamic variables and age among women and** 171 **men**

172 Plots of median CO, CI, SVR, and SVRI with age are presented in **Fig 2**. With age,  
173 median CO decreased for both sexes, being consistently lower among women (**Fig 2A**).  
174 Although median CI also decreased with age for both sexes, it was higher in women before age  
175 50 than men of the same age, becoming similar afterwards (**Fig 2B**). On the other hand, SVR  
176 increased with age in both sexes, being consistently higher among women (**Fig 2C**). Although  
177 SVRI increased in both groups, it was lower among women compared with men among  
178 individuals <50 years old, having a steeper increase with age among young women and  
179 becoming similar between the 2 groups among individuals  $\geq 50$  years of age (**Fig 2D**). These

180 results were consistent with those observed when analyzing individuals with SBP  $\geq 140$  mmHg  
181 or  $\geq 90$  mmHg only (**S1 Fig**).

182  
183 **Fig 2. Median Cardiac Output (A), Cardiac Index (B), Systemic Vascular Resistance (C),**  
184 **and Systemic Vascular Resistance Index (D) by Age Among Women and Men with**  
185 **Elevated Blood Pressure.** Solid lines represent the median. Dashed lines represent the 25<sup>th</sup> and  
186 75<sup>th</sup> percentile. Abbreviations: CO, cardiac output; CI, cardiac index; SVR, systemic vascular  
187 resistance; SVRI, systemic vascular resistance index.

188  
189 **Multivariable linear regression and propensity score matching**  
190 **sensitivity analysis**

191 Unadjusted and sequentially-adjusted female sex beta coefficients ( $\beta$ ) for CO, CI, SVR,  
192 and SVRI are presented in **Table 2**. After adjusting for age, BMI, and region, female sex was  
193 associated with lower cardiac output overall ( $\beta = -0.78$  [95% CI: -0.8, -0.75]), among those  $< 50$   
194 years old ( $\beta = -0.59$  [95% CI: -0.64, -0.54]), and among those  $\geq 50$  years old ( $\beta = -0.86$  [95% CI: -  
195 0.89, -0.83]). However, female sex was positively associated with CI only among those  $< 50$   
196 years ( $\beta = 0.07$  [95% CI: 0.04, 0.09]), having a negative association overall ( $\beta = -0.08$  [95% CI: -  
197 0.09, -0.06]) and among those  $\geq 50$  years of age ( $\beta = -0.15$  [95% CI: -0.16, -0.13]). On the other  
198 hand, female sex was associated with higher SVR overall ( $\beta = 229$  [95% CI: 221, 238]), among  
199 those  $< 50$  years ( $\beta = 140$  [95% CI: 128, 151]), and among those  $\geq 50$  years of age ( $\beta = 274$  [95%  
200 CI: 262, 285]). Lastly, female sex had a negative association with SVRI only among those  $< 50$   
201 years old ( $\beta = -31.7$  [95% CI: -51.2, -12.2]), having a positive association among those  $> 50$  years  
202 of age ( $\beta = 120.4$  [95% CI: 102.4, 138.5]) and among the entire study population ( $\beta = 73.5$  [95%

203 CI: 60.3, 86.8]). The direction and magnitude of these findings were mostly consistent with the  
 204 ones from the adjusted model that did not include BMI (Table 2).

205  
 206 **Table 2. Unadjusted and Sequentially-Adjusted Association of Female Sex with Cardiac**  
 207 **Output, Cardiac Index, Systemic Vascular Resistance, and Systemic Vascular Resistance**  
 208 **Index, Overall and by Age Categories.**

Hemodynamic Variable	Female Sex $\beta$ Coefficient (95% CI)		
	Unadjusted Model	Adjusted Model 1*	Adjusted Model 2†
<b>Cardiac Output, (L/min)</b>			
Overall	-1.07 (-1.1, -1.04)	-0.79 (-0.82, -0.77)	-0.78 (-0.8, -0.75)
<50 years old	-0.73 (-0.78, -0.68)	-0.67 (-0.71, -0.62)	-0.59 (-0.64, -0.54)
$\geq$ 50 years old	-0.90 (-0.93, -0.87)	-0.86 (-0.89, -0.83)	-0.86 (-0.89, -0.83)
<b>Cardiac Index, (L/min/m<sup>2</sup>)</b>			
Overall	-0.15 (-0.16, -0.13)	-0.01 (-0.03, 0) <sup>‡</sup>	-0.08 (-0.09, -0.06)
<50 years old	0.14 (0.12, 0.17)	0.19 (0.16, 0.21)	0.07 (0.04, 0.09)
$\geq$ 50 years old	-0.14 (-0.16, -0.12)	-0.12 (-0.14, -0.1)	-0.15 (-0.16, -0.13)
<b>Systemic Vascular Resistance, (dynes-sec-cm<sup>-5</sup>)</b>			
Overall	312 (303, 320)	225 (216, 233)	230 (221, 238)
<50 years old	156 (144, 167)	138 (127, 149)	140 (128, 151)
$\geq$ 50 years old	282 (271, 294)	271 (260, 282)	274 (262, 285)
<b>Systemic Vascular Resistance Index, (dynes-sec-cm<sup>-5</sup>-m<sup>2</sup>)</b>			
Overall	137.8 (123.7, 151.8)	6.0 (-7.6, 19.7) <sup>§</sup>	73.5 (60.2, 86.8)
<50 years old	-109.1 (-129.7, -88.6)	-146.9 (-166.6, -127.3)	-31.7 (-51.2, -12.2)
$\geq$ 50 years old	110.5 (91.7, 129.3)	88.5 (69.9, 107.2)	120.4 (102.4, 138.5)
* Model 1 was adjusted for age and region † Model 2 was adjusted for age, region, and body mass index ‡P value=0.16 §P value=0.39 All other P values <0.001			

209  
 210 These hemodynamic differences remained in the propensity score matching sensitivity  
 211 analysis (S2 Table) and in the sensitivity analysis among those with SBP  $\geq$ 140 mmHg or DBP

212  $\geq 90$  mmHg (**S3 Table**), although the magnitude of the SVRI difference among those younger  
213 than 50 years was not significant.

214

### 215 **Hemodynamic variables distribution overlap between women and men**

216 Density plots of CO and CI, by sex and age are shown in **Fig 3**. Overall, the CO showed a  
217 distribution overlap of 52.1% between women's and men's density plots (**Fig 3A**). Among those  
218 younger than 50 years, women's CO distribution was slightly shifted to the left compared with  
219 men's, with a 65.4% overlap between sexes (**Fig 3B**). On the other hand, among those older than  
220 50 years, CO distribution among women had higher kurtosis and was shifted to the left when  
221 compared with men, with an overlap between sexes of 55.6% (**Fig 3C**). The indexed variable  
222 (CI) distribution showed a greater overlap between sexes, reaching 79.6% overall, 80.8% among  
223 those <50 years old, and 82.6% among those  $\geq 50$  years old (**Figs 3D, 3E, and 3F**, respectively).

224

### 225 **Fig 3. Cardiac Output (A, B, and C) and Cardiac Index (D, E, and F) Density Plots Overlap**

226 **Between Women And Men with Elevated Blood Pressure by Age Category.** Abbreviations:

227 CO, cardiac output; CI, cardiac index; OA, overlapping area.

228

229 Density plots of SVR and SVRI by sex and age are shown in **Fig 4**. Distribution of SVR  
230 showed an overlap between men and women of 56.7%, with women's density plot having lower  
231 kurtosis and shifted to the right compared with men's (**Fig 4A**). Among those <50 years old,  
232 women's SVR distribution had less kurtosis and was slightly shifted to the right compared with  
233 men's, with an overlap between sexes of 72.1% (**Fig 4B**). On the other hand, among those  $\geq 50$   
234 years old, women's SVR distribution was shifted to the right compared with men's, with an

235 overlap of 61.4% between the 2 groups (**Fig 4C**). The indexed variable (SVRI), also increased in  
236 overlap between both sexes, reaching 82.4%, 78.3%, and 87.7% among the entire study  
237 population, among those <50 years old, and among those  $\geq 50$  years old, respectively (**Figs 4D,**  
238 **4E,** and **4F,** respectively).

239

240 **Fig 4. Systemic Vascular Resistance (A, B, and C), and Systemic Vascular Resistance Index**  
241 **(D, E, and F) Density Plots Overlap Between Women And Men with Elevated Blood**  
242 **Pressure by Age Category.** Abbreviations: SVR, systemic vascular resistance; SVRI, systemic  
243 vascular resistance index; OA, overlapping area.

244

245 When analyzing only those with SBP  $\geq 140$  mmHg or DBP  $\geq 90$  mmHg, the overlapping  
246 areas of the distribution of CO, CI, SVR, and SVRI were highly consistent with the ones from  
247 our main analysis (**S2 and S3 Figs**).

248

## 249 **Discussion**

250 In our study, we investigated sex differences in hemodynamic variables, mainly CI and  
251 SVRI, among adults presenting with elevated blood pressure. We found that, on average, young  
252 women have higher mean CI and lower SVRI than age-matched men, although the magnitude of  
253 the SVRI difference was significantly reduced when accounting for confounders. Notably, we  
254 also found that these hemodynamic differences between sexes were reversed among those older  
255 than 50 years of age, the mean age of menopause in China,[34] with women having lower mean  
256 CI and higher mean SVRI than men. Nonetheless, a key finding of our study was that, despite  
257 these overall differences, there is substantial hemodynamic heterogeneity within individuals of

258 the same sex and age: the overlapping area of the distribution plots of CI and SVRI ranged from  
259 nearly 80% among those younger than 50 years to nearly 90% among those older than 50 years.

260 Our results expand the existing knowledge in 2 major ways. First, while most studies  
261 have been performed on small samples or among young individuals,[5-7] our study allowed us to  
262 describe the hemodynamic sex differences in a much larger sample of individuals with elevated  
263 blood pressure, including older individuals. To the best of our knowledge this is the largest study  
264 that has compared hemodynamic variables and phenotypes between women and men across  
265 different age groups. Doing so is instrumental in these studies because of the cardiovascular risk  
266 changes associated with menopause.[18, 19, 34, 41] Second, our study is the first to estimate the  
267 full distribution of hemodynamic parameters by sex, rather than being limited to comparing the  
268 average values. This approach allowed us to describe for the first time that—besides significant  
269 average differences—sex is not a reliable indicator of the individual hemodynamic phenotype,  
270 particularly among those older than 50 years old where the distributions of CI and SVRI among  
271 women and men were almost identical.

272 Despite the geographical, sample size, and inclusion criteria differences, our results  
273 complement and are consistent with the findings from other studies in non-Asian populations[5-  
274 7] in which the authors found that, among hypertensive individuals, men had a higher CO and  
275 lower SVR than women. However, considering the well-known body composition differences  
276 between men and women,[42] we analyzed the hypertension phenotype using the body surface  
277 area adjusted values (CI and SVRI) and stratified by age, increasing the comparability of these  
278 variables between sexes, consistent with our previous studies.[43, 44] We found that despite the  
279 differences in mean CO and SVR, among those <50 years old hypertensive women were more  
280 likely to have a predominantly cardiac phenotype (high CI with normal/low SVRI) and less



281 likely to have a predominantly vascular phenotype (high SVRI with normal/low CI) compared  
282 with men of the same age. Interestingly, among those older than 50 years, women were more  
283 likely to present a predominantly vascular phenotype than men. One plausible explanation for  
284 such an observation is that, along with hormonal and environmental factors,[19] young women  
285 have a blunted alpha-adrenergic vasoconstriction response because of an increased beta-  
286 adrenergic vasodilatation[45] that disappears after menopause and that is absent in men.[46]  
287 This, however, does not fully explain the association between sex and blood pressure: compared  
288 with men, women have a steeper increase in SBP thorough life, even decades before  
289 menopause.[47] Altogether, such findings might suggest that the underlying mechanisms of  
290 elevated blood pressure might differ by sex, particularly among young individuals. The  
291 therapeutically implications of these sex differences are limited because of the high same-sex  
292 heterogeneity in these parameters that we observed. Beyond its potential implications for  
293 treatment adjustment or initiation,[8-10] understanding if these differences in hypertension  
294 phenotypes are implicated in the known sex differences in terms of risk of subsequent  
295 cardiovascular outcomes[48] is still uncertain and deserves further investigation. Furthermore,  
296 there is also a need for longitudinal studies that help us to understand how chronic exposure to  
297 different hypertension phenotypes is associated with clinical outcomes, and if there are sex-  
298 differences in such associations.

299 Our study also has important implications for personalizing the care of patients  
300 presenting to an outpatient clinic with elevated blood pressure. As hypertension remains as one  
301 of the biggest public health challenges worldwide,[49] there is urgency in determining possible  
302 ways of improving its treatment efficacy by using personalized therapies tailored to each  
303 patient's characteristics. Although we and other studies have shown that, on average, there are

304 significant hemodynamic differences by sex, we also found that there is substantial same-sex  
305 heterogeneity in the hemodynamic profile. Notably, as hypertension prevalence and arterial  
306 stiffening increases among women after menopause,[15, 18, 50] the distribution of CI and SVRI  
307 among those older than 50 years was almost the same between women and men. Thus, our study  
308 indicates that sex alone is not a good proxy of the underlying hemodynamic patterns of patients  
309 with elevated blood pressure and should not be used clinically to assume the hypertension  
310 phenotype. Instead, it is necessary to measure these parameters directly if information about the  
311 hemodynamic profile is considered necessary to guide the antihypertensive therapy.

312

## 313 **Limitations**

314 The results from our study should be interpreted in light of the following limitations. First, our  
315 findings only represent a snapshot of an individual's hemodynamic status, preventing us from  
316 assessing longitudinal clinical outcomes and pathologic adaptations that may occur with long-  
317 term exposure to a particular hypertension phenotype, including structural and physiological  
318 changes in heart and vessels.[51, 52]

319         Second, although we had highly detailed hemodynamic information of each individual,  
320 the sociodemographic and clinical information (including comorbidities that may affect  
321 hemodynamic status) available to our analyses was limited. Of great importance is the lack of  
322 information regarding current antihypertensive medications usage, which could alter the  
323 hemodynamic phenotype and inclusion criteria (e.g. beta-blockers lowering CO or a patient with  
324 controlled hypertension not being included). However, studies have shown that hypertension  
325 treatment and blood pressure control rates are low in China,[53-55] though they are higher  
326 among women than in men, suggesting that the majority of the patients in our study would be

327 untreated and that most individuals with hypertension would have been included. Nonetheless,  
328 our results represent participants' hemodynamic status at the time of examination in an  
329 outpatient clinic, regardless of their medications, which could help guide the treatment initiation  
330 or adjustment based on the underlying hemodynamic derangement among patients with  
331 uncontrolled blood pressure. Additionally, although menopause is a key determinant of blood  
332 pressure regulation, we did not have this self-reported event from our participants. However, for  
333 our analysis we used the average age of menopause in China and the results were consistent with  
334 this hemodynamic shift among women around age 50 years. Lastly, we did not have information  
335 on participants' smoking status or smoking history, factors associated with hypertension and  
336 increased arterial stiffness, although the latter is less certain.[56, 57] Smoking is one of the major  
337 public health challenges among Chinese men, with a prevalence of nearly 1 in 2 among them and  
338 only around 2% among women.[58, 59] The impact of smoking on the hypertension phenotype  
339 and if such an association is modified by sex remains to be studied in detail.

340 Third, a single BP measurement was recorded per participant, which could have affected  
341 the precision in this variable. However, all study centers followed the same standardized protocol  
342 for men and women, as described in the Methods section, to reduce inter-observer variability.  
343 Moreover, such a compromise in precision would most likely shift the observed sex differences  
344 towards the null rather than towards significance.

345 Fourth, although we performed a robust main analysis, which included adjustment for  
346 multiple confounders, and a sensitivity analysis that used propensity score matching, we cannot  
347 rule out that the differences observed between men and women were due to residual  
348 confounding.

349

## 350 **Conclusions**

351           Women and men with elevated blood pressure in China have differences in the average  
352 values of the hemodynamic determinants of blood pressure. However, the magnitude of such  
353 differences is significantly reduced with age and there is substantial overlap in the distribution of  
354 the hemodynamic variables. This indicates that sex alone is insufficient to infer the underlying  
355 hypertension phenotype.

## 356 **Acknowledgments**

357 The authors would like to acknowledge the support of Mr. Zhang Ligang, CEO of iKang Health  
358 Group, for the permission to use the data.

359 **Source of funding**

360 The authors received no specific funding for this work.

## 361 **Disclosures**

362 **Yuan Lu** is supported by the National Heart, Lung, and Blood Institute (K12HL138037) and the  
363 Yale Center for Implementation Science. **Erica S. Spatz** receives support from the Food and  
364 Drug Administration to support projects within the Yale-Mayo Clinic Center of Excellence in  
365 Regulatory Science and Innovation (CERSI); the National Institute on Minority Health and  
366 Health Disparities (U54MD010711-01) to study precision-based approaches to diagnosing and  
367 preventing hypertension; and the National Institute of Biomedical Imaging and Bioengineering  
368 (R01EB028106-01) to study a cuff-less blood pressure device. **Xin Zheng** is supported by the  
369 CAMS Innovation Fund for Medical Science (2016-I2M-1-006), the National Key Research and  
370 Development Program (2016YFE0103800) from the Ministry of Science and Technology of  
371 China. **Hui Lu** is supported by the National Key R&D Program of China (2018YFC0910500)  
372 and Neil Shen's SJTU Medical Research Fund. **Zheng J. Ma** is affiliated with Beijing Li-Heng  
373 Medical Technologies, Ltd, which designed the ICG device used in this study. This affiliation  
374 did not play a role in the study design, data collection and analysis, decision to publish, or  
375 preparation of the manuscript. In the past three years, **Harlan Krumholz** received expenses  
376 and/or personal fees from UnitedHealth, Element Science, Aetna, Reality Labs,  
377 Tesseract/4Catalyst, F-Prime, the Siegfried and Jensen Law Firm, Arnold and Porter Law Firm,  
378 and Martin/Baughman Law Firm. He is a co-founder of Refactor Health and HugoHealth, and is  
379 associated with contracts, through Yale New Haven Hospital, from the Centers for Medicare &  
380 Medicaid Services and through Yale University from Johnson & Johnson. Such competing  
381 interests do not alter our adherence to PLOS ONE policies on sharing data and materials. The  
382 other co-authors report no potential competing interests.

## 383 **References**

- 384 1. Hart EC, Charkoudian N, Wallin BG, Curry TB, Eisenach J, Joyner MJ. Sex and ageing  
385 differences in resting arterial pressure regulation: the role of the beta-adrenergic receptors. *J*  
386 *Physiol.* 2011;589(Pt 21):5285-97. Epub 2011/08/24. doi: 10.1113/jphysiol.2011.212753.  
387 PubMed PMID: 21859824; PubMed Central PMCID: PMCPMC3225680.
- 388 2. Hart EC, Charkoudian N, Wallin BG, Curry TB, Eisenach JH, Joyner MJ. Sex  
389 differences in sympathetic neural-hemodynamic balance: implications for human blood pressure  
390 regulation. *Hypertension.* 2009;53(3):571-6. Epub 2009/01/28. doi:  
391 10.1161/hypertensionaha.108.126391. PubMed PMID: 19171792; PubMed Central PMCID:  
392 PMCPMC3733790.
- 393 3. Reckelhoff JF. Sex differences in regulation of blood pressure. *Adv Exp Med Biol.*  
394 2018;1065:139-51. Epub 2018/07/28. doi: 10.1007/978-3-319-77932-4\_9. PubMed PMID:  
395 30051382.
- 396 4. Briant LJB, Charkoudian N, Hart EC. Sympathetic regulation of blood pressure in  
397 normotension and hypertension: when sex matters. *Exp Physiol.* 2016;101(2):219-29. doi:  
398 10.1113/ep085368.
- 399 5. Nardin C, Maki-Petaja KM, Miles KL, Yasmin, McDonnell BJ, Cockcroft JR, et al.  
400 Cardiovascular phenotype of elevated blood pressure differs markedly between young males and  
401 females: The Enigma Study. *Hypertension.* 2018;72(6):1277-84. Epub 2019/02/15. doi:  
402 10.1161/hypertensionaha.118.11975. PubMed PMID: 30763511; PubMed Central PMCID:  
403 PMCPMC6221425.



- 404 6. Ferrario CM, Jessup JA, Smith RD. Hemodynamic and hormonal patterns of untreated  
405 essential hypertension in men and women. *Ther Adv Cardiovasc Dis.* 2013;7(6):293-305. doi:  
406 10.1177/1753944713513221. PubMed PMID: 24280597.
- 407 7. Krzesinski P, Stanczyk A, Gielerak G, Uzieblo-Zyczkowska B, Kurpaska M, Piotrowicz  
408 K, et al. Sex determines cardiovascular hemodynamics in hypertension. *J Hum Hypertens.*  
409 2015;29(10):610-7. Epub 2015/01/30. doi: 10.1038/jhh.2014.134. PubMed PMID: 25631222.
- 410 8. Smith RD, Levy P, Ferrario CM. Value of noninvasive hemodynamics to achieve blood  
411 pressure control in hypertensive subjects. *Hypertension.* 2006;47(4):771-7. doi:  
412 doi:10.1161/01.HYP.0000209642.11448.e0.
- 413 9. Krzeński P, Gielerak GG, Kowal JJ. A "patient-tailored" treatment of hypertension with  
414 use of impedance cardiography: a randomized, prospective and controlled trial. *Med Sci Monit.*  
415 2013;19:242-50. Epub 2013/04/06. doi: 10.12659/msm.883870. PubMed PMID: 23558598;  
416 PubMed Central PMCID: PMC3659156.
- 417 10. Taler SJ, Textor SC, Augustine JE. Resistant hypertension. *Hypertension*  
418 2002;39(5):982-8. doi: doi:10.1161/01.HYP.0000016176.16042.2F.
- 419 11. Lu Y, Wang L, Wang H, Gu J, Ma ZJ, Lian Z, et al. Effectiveness of an impedance  
420 cardiography guided treatment strategy to improve blood pressure control in a real-world setting:  
421 results from a pragmatic clinical trial. *Open Heart.* 2021;8(2). doi: 10.1136/openhrt-2021-  
422 001719. PubMed PMID: 34580169; PubMed Central PMCID: PMC3659156.
- 423 12. Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Himmelfarb CD, et al.  
424 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the  
425 Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report  
426 of the American College of Cardiology/American Heart Association Task Force on Clinical

- 427 Practice Guidelines. Hypertension 2018;71(6):e13-e115. doi:  
428 doi:10.1161/HYP.0000000000000065.
- 429 13. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018  
430 ESC/ESH Guidelines for the management of arterial hypertension: The task force for the  
431 management of arterial hypertension of the European Society of Cardiology (ESC) and the  
432 European Society of Hypertension (ESH). Eur Heart J. 2018;39(33):3021-104. doi:  
433 10.1093/eurheartj/ehy339.
- 434 14. Peralta CA, Katz R, Newman AB, Psaty BM, Odden MC. Systolic and diastolic blood  
435 pressure, incident cardiovascular events, and death in elderly persons: the role of functional  
436 limitation in the Cardiovascular Health Study. Hypertension. 2014;64(3):472-80. Epub  
437 2014/06/18. doi: 10.1161/hypertensionaha.114.03831. PubMed PMID: 24935945; PubMed  
438 Central PMCID: PMC4134400.
- 439 15. Cheng S, Xanthakis V, Sullivan LM, Vasan RS. Blood pressure tracking over the adult  
440 life course: patterns and correlates in the Framingham heart study. Hypertension  
441 2012;60(6):1393-9. Epub 2012/10/31. doi: 10.1161/hypertensionaha.112.201780. PubMed  
442 PMID: 23108660; PubMed Central PMCID: PMC3499677.
- 443 16. Vishram JK, Borglykke A, Andreassen AH, Jeppesen J, Ibsen H, Jorgensen T, et al.  
444 Impact of age on the importance of systolic and diastolic blood pressures for stroke risk: the  
445 MONica, Risk, Genetics, Archiving, and Monograph (MORGAM) Project. Hypertension.  
446 2012;60(5):1117-23. Epub 2012/09/26. doi: 10.1161/hypertensionaha.112.201400. PubMed  
447 PMID: 23006731.

- 448 17. Coylewright M, Reckelhoff JF, Ouyang P. Menopause and hypertension: an age-old  
449 debate. *Hypertension*. 2008;51(4):952-9. Epub 2008/02/09. doi:  
450 10.1161/hypertensionaha.107.105742. PubMed PMID: 18259027.
- 451 18. Zhou Y, Zhou X, Guo X, Sun G, Li Z, Zheng L, et al. Prevalence and risk factors of  
452 hypertension among pre- and post-menopausal women: a cross-sectional study in a rural area of  
453 northeast China. *Maturitas*. 2015;80(3):282-7. Epub 2015/01/08. doi:  
454 10.1016/j.maturitas.2014.12.001. PubMed PMID: 25563399.
- 455 19. Colafella KMM, Denton KM. Sex-specific differences in hypertension and associated  
456 cardiovascular disease. *Nat Rev Nephrol*. 2018;14(3):185-201. Epub 2018/01/31. doi:  
457 10.1038/nrneph.2017.189. PubMed PMID: 29380817.
- 458 20. Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, et al. Heart Disease  
459 and Stroke Statistics-2017 Update: A Report From the American Heart Association. *Circulation*.  
460 2017;135(10):e146-e603. Epub 2017/01/27. doi: 10.1161/cir.0000000000000485. PubMed  
461 PMID: 28122885; PubMed Central PMCID: PMC5408160.
- 462 21. Belardinelli R, Ciampani N, Costantini C, Blandini A, Purcaro A. Comparison of  
463 impedance cardiography with thermodilution and direct Fick methods for noninvasive  
464 measurement of stroke volume and cardiac output during incremental exercise in patients with  
465 ischemic cardiomyopathy. *Am J Cardiol*. 1996;77(15):1293-301. Epub 1996/06/15. PubMed  
466 PMID: 8677869.
- 467 22. McFetridge-Durdle JA, Routledge FS, Parry MJE, Dean CRT, Tucker B. Ambulatory  
468 impedance cardiography in hypertension: a validation study. *Eur J Cardiovasc Nurs*.  
469 2008;7(3):204-13. doi: 10.1016/j.ejcnurse.2007.10.003.

- 470 23. Drazner MH, Thompson B, Rosenberg PB, Kaiser PA, Boehrer JD, Baldwin BJ, et al.  
471 Comparison of impedance cardiography with invasive hemodynamic measurements in patients  
472 with heart failure secondary to ischemic or nonischemic cardiomyopathy. *Am J Cardiol.*  
473 2002;89(8):993-5. Epub 2002/04/13. PubMed PMID: 11950446.
- 474 24. Greenberg BH, Hermann DD, Pranulis MF, Lazio L, Cloutier D. Reproducibility of  
475 impedance cardiography hemodynamic measures in clinically stable heart failure patients.  
476 *Congest Heart Fail.* 2000;6(2):74-80. Epub 2002/05/25. doi: 10.1111/j.1527-5299.2000.80140.x.  
477 PubMed PMID: 12029190.
- 478 25. Bernstein DP. A new stroke volume equation for thoracic electrical bioimpedance: theory  
479 and rationale. *Crit Care Med.* 1986;14(10):904-9. Epub 1986/10/01. PubMed PMID: 3757533.
- 480 26. Sherwood A, Allen MT, Fahrenberg J, Kelsey RM, Lovallo WR, van Doornen LJ.  
481 Methodological guidelines for impedance cardiography. *Psychophysiology.* 1990;27(1):1-23.  
482 Epub 1990/01/01. PubMed PMID: 2187214.
- 483 27. Yancy C, Abraham WT. Noninvasive hemodynamic monitoring in heart failure:  
484 utilization of impedance cardiography. *Congest Heart Fail.* 2003;9(5):241-50. Epub 2003/10/18.  
485 PubMed PMID: 14564142.
- 486 28. Ma L-y. Development and application of the latest model of the cardiac hemodynamics  
487 monitoring system. *Chinese J Cardiovasc Med.* 2008;13(1):72-73.
- 488 29. An X-g, Zhao Y, Gao J. Clinic evaluation of noninvasive hemodynamic monitoring in  
489 patients undergoing coronary artery surgery. *Chin J Cardiovasc Rev.* 2008;6(2):96-98.
- 490 30. Hong H, Jin X, Pan C, Gao X, Liu M, Jiang H, Ge J. Analysis of the correlation between  
491 non-invasive hemodynamic monitor and cardiac echocardiography on the evaluation of cardiac  
492 function. *Chinese Journal of Medical Instrumentation.* 2009;33:328-331.

- 493 31. Chen W, Huang D, Zeng J, Deng R, Deng G, Chen W, Zou Y. Application of  
494 noninvasive cardiac hemodynamic monitor for ICU critically ill patients. *Hainan Medical*  
495 *Journal*. 2018;29:15.
- 496 32. Dorjgochoo T, Kallianpur A, Gao YT, Cai H, Yang G, Li H, et al. Dietary and lifestyle  
497 predictors of age at natural menopause and reproductive span in the Shanghai Women's Health  
498 Study. *Menopause*. 2008;15(5):924-33. Epub 2008/07/05. doi: 10.1097/gme.0b013e3181786adc.  
499 PubMed PMID: 18600186; PubMed Central PMCID: PMCPMC2615483.
- 500 33. Wang M, Gong WW, Hu RY, Wang H, Guo Y, Bian Z, et al. Age at natural menopause  
501 and associated factors in adult women: Findings from the China Kadoorie Biobank study in  
502 Zhejiang rural area. *PLoS One*. 2018;13(4):e0195658. Epub 2018/04/19. doi:  
503 10.1371/journal.pone.0195658. PubMed PMID: 29668705; PubMed Central PMCID:  
504 PMCPMC5905992.
- 505 34. Song L, Shen L, Li H, Liu B, Zheng X, Zhang L, et al. Age at natural menopause and  
506 hypertension among middle-aged and older Chinese women. *J Hypertens*. 2018;36(3):594-600.  
507 Epub 2017/10/11. doi: 10.1097/hjh.0000000000001585. PubMed PMID: 29016533.
- 508 35. WHO Expert Consultation. Appropriate body-mass index for Asian populations and its  
509 implications for policy and intervention strategies. *Lancet*. 2004;363(9403):157-63. Epub  
510 2004/01/17. doi: 10.1016/s0140-6736(03)15268-3. PubMed PMID: 14726171.
- 511 36. Wannenburg T, Little WC. Regulation of cardiac output. In: Jeremias A, Brown DL,  
512 editors. *Cardiac Intensive Care*, Second ed. Philadelphia: W.B. Saunders; 2010. p. 61-8.
- 513 37. Gidwani UK, Mohanty B, Chatterjee K. The pulmonary artery catheter: a critical  
514 reappraisal. *Cardiol Clin*. 2013;31(4):545-65, viii. Epub 2013/11/06. doi:  
515 10.1016/j.ccl.2013.07.008. PubMed PMID: 24188220.

- 516 38. Cole TJ, Green PJ. Smoothing reference centile curves: the LMS method and penalized  
517 likelihood. *Stat Med*. 1992;11:1305-1319.
- 518 39. Stuart EA, King G, Imai K, Ho D. MatchIt: nonparametric preprocessing for parametric  
519 causal inference. *J Stat Softw*. 2011.
- 520 40. 2018 Chinese Guidelines for Prevention and Treatment of Hypertension-A report of the  
521 Revision Committee of Chinese Guidelines for Prevention and Treatment of Hypertension. *J*  
522 *Geriatr Cardiol*. 2019;16(3):182-241. Epub 2019/05/14. doi: 10.11909/j.issn.1671-  
523 5411.2019.03.014. PubMed PMID: 31080465; PubMed Central PMCID: PMC6500570
- 524 41. Khoudary SRE, Aggarwal B, Beckie TM, Hodis HN, Johnson AE, Langer RD, et al.  
525 Menopause transition and cardiovascular disease risk: implications for timing of early  
526 prevention: a scientific statement from the American Heart Association. *Circulation*.  
527 2020;142(25):e506-e32. doi: doi:10.1161/CIR.0000000000000912.
- 528 42. He X, Li Z, Tang X, Zhang L, Wang L, He Y, et al. Age- and sex-related differences in  
529 body composition in healthy subjects aged 18 to 82 years. *Medicine*. 2018;97(25):e11152. doi:  
530 10.1097/md.0000000000011152. PubMed PMID: 00005792-201806220-00052.
- 531 43. Mahajan S, Gu J, Caraballo C, Lu Y, Spatz ES, Zhao H, et al. Relationship of age with  
532 the hemodynamic parameters in individuals with elevated blood pressure. *J Am Geriatr Soc*.  
533 2020 Jul;68(7):1520-1528. doi: 10.1111/jgs.16411. Epub 2020 Mar 25. PMID: 32212398.
- 534 44. Mahajan S, Gu J, Lu Y, Khara R, Spatz ES, Zhang M, et al. Hemodynamic phenotypes of  
535 hypertension based on cardiac output and systemic vascular resistance. *Am J Med*. 2020  
536 Apr;133(4):e127-e139. doi: 10.1016/j.amjmed.2019.08.042. Epub 2019 Sep 13. PMID:  
537 31525336.

- 538 45. Hart EC, Charkoudian N, Wallin BG, Curry TB, Eisenach J, Joyner MJ. Sex and ageing  
539 differences in resting arterial pressure regulation: the role of the  $\beta$ -adrenergic receptors. *J*  
540 *Physiol.* 2011 Nov 1;589(Pt 21):5285-97. doi: 10.1113/jphysiol.2011.212753. Epub 2011 Aug  
541 22. PMID: 21859824; PMCID: PMC3225680.
- 542 46. Joyner MJ, Wallin BG, Charkoudian N. Sex differences and blood pressure regulation in  
543 humans. *Exp Physiol.* 2016 Mar;101(3):349-55. doi: 10.1113/EP085146. Epub 2015 Aug 16.  
544 PMID: 26152788.
- 545 47. Ji H, Kim A, Ebinger JE, Niiranen TJ, Claggett BL, Merz CNB, et al. Sex differences in  
546 blood pressure trajectories over the life course. *JAMA cardiology.* 2020;5(3):19-26.
- 547 48. Ji H, Niiranen TJ, Rader F, Henglin M, Kim A, Ebinger JE, et al. Sex differences in  
548 blood pressure associations with cardiovascular outcomes. *Circulation.* 2021;143(7):761-3. doi:  
549 doi:10.1161/CIRCULATIONAHA.120.049360.
- 550 49. Global, regional, and national comparative risk assessment of 84 behavioural,  
551 environmental and occupational, and metabolic risks or clusters of risks for 195 countries and  
552 territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.  
553 *Lancet.* 2018;392(10159):1923-94. Epub 2018/11/30. doi: 10.1016/s0140-6736(18)32225-6.  
554 PubMed PMID: 30496105; PubMed Central PMCID: PMC6227755.
- 555 50. Lu Y, Pechlaner R, Cai J, Yuan H, Huang Z, Yang G, et al. Trajectories of age-related  
556 arterial stiffness in Chinese men and women. *J Am Coll Cardiol.* 2020 Mar 3;75(8):870-880. doi:  
557 10.1016/j.jacc.2019.12.039. PMID: 32130922.
- 558 51. Julius S. Transition from high cardiac output to elevated vascular resistance in  
559 hypertension. *Am Heart J.* 1988;116(2 Pt 2):600-6. Epub 1988/08/01. doi: 10.1016/0002-  
560 8703(88)90557-1. PubMed PMID: 3293404.

- 561 52. Falkner B. Cardiac output versus total peripheral resistance. *Hypertension*. 2018  
562 Nov;72(5):1093-1094. doi: 10.1161/HYPERTENSIONAHA.118.11963. PMID: 30354830.
- 563 53. Lu J, Lu Y, Wang X, Li X, Linderman GC, Wu C, et al. Prevalence, awareness,  
564 treatment, and control of hypertension in China: data from 1.7 million adults in a population-  
565 based screening study (China PEACE Million Persons Project). *Lancet*. 2017;390(10112):2549-  
566 58. Epub 2017/11/06. doi: 10.1016/s0140-6736(17)32478-9. PubMed PMID: 29102084.
- 567 54. Wang Z, Chen Z, Zhang L, Wang X, Hao G, Zhang Z, et al. Status of hypertension in  
568 China: Results from the China Hypertension Survey, 2012-2015. *Circulation*.  
569 2018;137(22):2344-56. Epub 2018/02/17. doi: 10.1161/circulationaha.117.032380. PubMed  
570 PMID: 29449338.
- 571 55. Wang J, Zhang L, Wang F, Liu L, Wang H. Prevalence, awareness, treatment, and  
572 control of hypertension in China: results from a national survey. *Am J Hypertens*.  
573 2014;27(11):1355-61. Epub 2014/04/05. doi: 10.1093/ajh/hpu053. PubMed PMID: 24698853;  
574 PubMed Central PMCID: PMC4263934.
- 575 56. Doonan RJ, Hausvater A, Scallan C, Mikhailidis DP, Pilote L, Daskalopoulou SS. The  
576 effect of smoking on arterial stiffness. *Hypertension Research*. 2010;33(5):398-410. doi:  
577 10.1038/hr.2010.25.
- 578 57. Camplain R, Meyer ML, Tanaka H, Palta P, Agarwal SK, Aguilar D, et al. Smoking  
579 behaviors and arterial stiffness measured by pulse wave velocity in older adults: The  
580 Atherosclerosis Risk in Communities (ARIC) Study. *Am J Hypertens*. 2016;29(11):1268-75.  
581 Epub 2015/12/15. doi: 10.1093/ajh/hpv189. PubMed PMID: 26657706; PubMed Central  
582 PMCID: PMC4555735.



- 583 58. Parascandola M, Xiao L. Tobacco and the lung cancer epidemic in China. *Transl Lung*  
584 *Cancer Res.* 2019;8(Suppl 1):S21-s30. Epub 2019/06/19. doi: 10.21037/tlcr.2019.03.12. PubMed  
585 PMID: 31211103; PubMed Central PMCID: PMC6546632.
- 586 59. Wang M, Luo X, Xu S, Liu W, Ding F, Zhang X, et al. Trends in smoking prevalence  
587 and implication for chronic diseases in China: serial national cross-sectional surveys from 2003  
588 to 2013. *Lancet Respir Med.* 2019;7(1):35-45. Epub 2018/11/30. doi: 10.1016/s2213-  
589 2600(18)30432-6. PubMed PMID: 30482646.
- 590

591 **Supporting information**

592 **S1 Fig. Median Cardiac Output, Cardiac Index, Systemic Vascular Resistance, and**  
593 **Systemic Vascular Resistance Index by Age Among Women and Men with Systolic Blood**  
594 **Pressure  $\geq 140$  mmHg or Diastolic Blood Pressure  $\geq 90$  mmHg.**

595  
596 **S2 Fig. Cardiac Output and Cardiac Index Density Plots Overlap Between Women And**  
597 **Men with Systolic Blood Pressure  $\geq 140$  mmHg or Diastolic Blood Pressure  $\geq 90$  mmHg, by**  
598 **Age Category.**

599  
600 **S3 Fig. Systemic Vascular Resistance and Systemic Vascular Resistance Index Density**  
601 **Plots Overlap Between Women And Men with Systolic Blood Pressure  $\geq 140$  mmHg or**  
602 **Diastolic Blood Pressure  $\geq 90$  mmHg, by Age Category.**

603  
604 **S1 Table. Sex Differences in Clinical and Hemodynamic Variables by Age Group Among**  
605 **Adults With Systolic Blood Pressure  $\geq 140$  mmHg or Diastolic Blood Pressure  $\geq 90$  mmHg.**

606  
607 **S2 Table. Sex Differences In Clinical And Hemodynamic Variables By Nearest Neighbor**  
608 **Propensity Score Matched Subgroups.**

609  
610 **S3 Table. Unadjusted and Sequentially-Adjusted Association of Female Sex with Cardiac**  
611 **Output, Cardiac Index, Systemic Vascular Resistance, and Systemic Vascular Resistance**

612 **Index, Overall and by Age Categories Among Adults with Systolic Blood Pressure  $\geq 140$**

613 **mmHg or Diastolic Blood Pressure  $\geq 90$  mmHg, by Age Category.**

614

**Individuals with ICG  
measurements**  
January 2012 – October 2018  
N = 116,851

**Excluded Individuals = 71,769**

839 due to age <20 or >80 years

1814 due to outlier values of:





- a) Weight (<40kg or >140kg): N = 266
- b) Height (<120 cm or >220 cm): N = 7
- c) DBP (<50 mmHg or >150 mmHg): N = 479
- d) SBP (<80 mmHg or >250 mmHg): N = 47
- e) SV (<25 ml/beat or >180 ml/beat): N = 249
- f) HR (<30 bpm or >200 bpm): N = 33
- g) Z0 (<15 ohm or >45 ohm): N = 733







69,116 due to normal blood pressure values






**Included Participants with  
Accurate Measurements and  
Elevated Blood Pressure**  
N = 45,082

**Women**  
n = 15,888 (35.2%)

**Men**  
n = 29,194 (64.8%)

**CO, Median****CI, Median****SVR, Median****SVRI, Median**

**A, All****B, < 50 years old****C,  $\geq 50$  years old****D, All****E, < 50 years old****F,  $\geq 50$  years old**

**A, All****B, < 50 years old****C, >= 50 years old****D, All****E, < 50 years old****F, >= 50 years old**